Gene Review:
TNFRSF11B - tumor necrosis factor receptor superfamily...
Homo sapiens
Synonyms:
OCIF, OPG, Osteoclastogenesis inhibitory factor, Osteoprotegerin, TR1, ...
Allan Lawrie,
Findlay,
Jay Suntharalingam,
Abrahamsen,
Fawkner,
Finnegan,
Franke,
Podgornik,
Borset,
Shipman,
Al-Fakhri,
Rettmer,
Takahashi,
Haynes,
Hjertner,
Hegde,
Beck-Nielsen,
Sheila Francis,
Eriksen,
Diamond,
Rogers,
Schoppet,
Peter Croucher,
Standal,
Zannettino,
Holen,
David Crossman,
Suda,
David Evans,
Hannon,
Dibbelt,
Sundan,
Gamble,
Hegedüs,
Seidel,
Saleh,
Jimi,
Rudolf,
Love,
Barth,
Banovic,
Martin,
Whyte,
Elizabeth Waterman,
Nicholas Morrell,
Mulley,
Katz,
Stoeckelhuber,
Mumm,
Maisch,
Naot,
Sanderson,
Wallace,
Holding,
Preissner,
Bergmann-Koester,
King,
Cundy,
Waage,
Plesner,
Udagawa,
McAlister,
Mark Southwood,
Obrecht,
To,
Gillespie,
Grey,
Christopher Newman,
Reid,
Middleton-Hardie,
Seidel,
Schweiger,
Shipman,
Hofbauer,
Kahl,
Greggersen,
Kostakis,
Stilgren,
Atkins,
Jones,
Farrugia,
Cornish,
Greenfield,
Eastell,
Callon,
Chong,
Croucher,
- T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Colucci, S., Brunetti, G., Rizzi, R., Zonno, A., Mori, G., Colaianni, G., Del Prete, D., Faccio, R., Liso, A., Capalbo, S., Liso, V., Zallone, A., Grano, M. Blood (2004)
- Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Shipman, C.M., Croucher, P.I. Cancer Res. (2003)
- Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Zhang, X.D., Franco, A., Myers, K., Gray, C., Nguyen, T., Hersey, P. Cancer Res. (1999)
- In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. Onyia, J.E., Miles, R.R., Yang, X., Halladay, D.L., Hale, J., Glasebrook, A., McClure, D., Seno, G., Churgay, L., Chandrasekhar, S., Martin, T.J. J. Bone Miner. Res. (2000)
- Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat. Yamamoto, M., Murakami, T., Nishikawa, M., Tsuda, E., Mochizuki, S., Higashio, K., Akatsu, T., Motoyoshi, K., Nagata, N. Endocrinology (1998)
- CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. Vega, D., Maalouf, N.M., Sakhaee, K. J. Clin. Endocrinol. Metab. (2007)
- OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. De Toni, E.N., Thieme, S.E., Herbst, A., Behrens, A., Stieber, P., Jung, A., Blum, H., Göke, B., Kolligs, F.T. Clin. Cancer Res. (2008)
- Osteoprotegerin Lys3Asn polymorphism and the risk of fracture in older women. Moffett, S.P., Oakley, J.I., Cauley, J.A., Lui, L.Y., Ensrud, K.E., Taylor, B.C., Hillier, T.A., Hochberg, M.C., Li, J., Cayabyab, S., Lee, J.M., Peltz, G., Cummings, S.R., Zmuda, J.M. J. Clin. Endocrinol. Metab. (2008)
- Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Jorsal, A., Tarnow, L., Flyvbjerg, A., Parving, H.H., Rossing, P., Rasmussen, L.M. Diabetologia (2008)
- Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. Galluzzi, F., Stagi, S., Salti, R., Toni, S., Piscitelli, E., Simonini, G., Falcini, F., Chiarelli, F. Eur. J. Endocrinol. (2005)
- Serum osteoprotegerin in adolescent girls with anorexia nervosa. Misra, M., Soyka, L.A., Miller, K.K., Herzog, D.B., Grinspoon, S., De Chen, D., Neubauer, G., Klibanski, A. J. Clin. Endocrinol. Metab. (2003)
- Plasma osteoprotegerin as a biochemical marker for vascular dementia and Alzheimer's disease. Emanuele, E., Peros, E., Scioli, G.A., D'Angelo, A., Olivieri, C., Montagna, L., Geroldi, D. Int. J. Mol. Med. (2004)
- Bone mineral density, bone turnover, and osteoprotegerin in depressed women with and without borderline personality disorder. Kahl, K.G., Greggersen, W., Rudolf, S., Stoeckelhuber, B.M., Bergmann-Koester, C.U., Dibbelt, L., Schweiger, U. Psychosomatic medicine. (2006)
- Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Honore, P., Luger, N.M., Sabino, M.A., Schwei, M.J., Rogers, S.D., Mach, D.B., O'keefe, P.F., Ramnaraine, M.L., Clohisy, D.R., Mantyh, P.W. Nat. Med. (2000)
- Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M.T., Martin, T.J. Endocr. Rev. (1999)
- Concerted action of androgens and mechanical strain shifts bone metabolism from high turnover into an osteoanabolic mode. Liegibel, U.M., Sommer, U., Tomakidi, P., Hilscher, U., Van Den Heuvel, L., Pirzer, R., Hillmeier, J., Nawroth, P., Kasperk, C. J. Exp. Med. (2002)
- Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. Nagasaki, T., Inaba, M., Jono, S., Hiura, Y., Tahara, H., Shirakawa, K., Onoda, N., Ishikawa, T., Ishimura, E., Nishizawa, Y. Eur. J. Endocrinol. (2005)
- Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Standal, T., Seidel, C., Hjertner, Ø., Plesner, T., Sanderson, R.D., Waage, A., Borset, M., Sundan, A. Blood (2002)
- Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. Rogers, A., Saleh, G., Hannon, R.A., Greenfield, D., Eastell, R. J. Clin. Endocrinol. Metab. (2002)
- Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment. Mossetti, G., Rendina, D., De Filippo, G., Viceconti, R., Di Domenico, G., Cioffi, M., Postiglione, L., Nunziata, V. Bone (2005)
- The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Tannehill-Gregg, S.H., Levine, A.L., Nadella, M.V., Iguchi, H., Rosol, T.J. Clin. Exp. Metastasis (2006)
- A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Cundy, T., Hegde, M., Naot, D., Chong, B., King, A., Wallace, R., Mulley, J., Love, D.R., Seidel, J., Fawkner, M., Banovic, T., Callon, K.E., Grey, A.B., Reid, I.R., Middleton-Hardie, C.A., Cornish, J. Hum. Mol. Genet. (2002)
- Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. Chong, B., Hegde, M., Fawkner, M., Simonet, S., Cassinelli, H., Coker, M., Kanis, J., Seidel, J., Tau, C., Tüysüz, B., Yüksel, B., Love, D. J. Bone Miner. Res. (2003)
- Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin. Daroszewska, A., Hocking, L.J., McGuigan, F.E., Langdahl, B., Stone, M.D., Cundy, T., Nicholson, G.C., Fraser, W.D., Ralston, S.H. J. Bone Miner. Res. (2004)
- Osteoprotegerin deficiency and juvenile Paget's disease. Whyte, M.P., Obrecht, S.E., Finnegan, P.M., Jones, J.L., Podgornik, M.N., McAlister, W.H., Mumm, S. N. Engl. J. Med. (2002)
- Expression of osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human dental mesenchymal cells and epithelial cells. Sakata, M., Shiba, H., Komatsuzawa, H., Fujita, T., Ohta, K., Sugai, M., Suginaka, H., Kurihara, H. J. Bone Miner. Res. (1999)
- Characterization of structural domains of human osteoclastogenesis inhibitory factor. Yamaguchi, K., Kinosaki, M., Goto, M., Kobayashi, F., Tsuda, E., Morinaga, T., Higashio, K. J. Biol. Chem. (1998)
- Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Lawrie, A., Waterman, E., Southwood, M., Evans, D., Suntharalingam, J., Francis, S., Crossman, D., Croucher, P., Morrell, N., Newman, C. Am. J. Pathol. (2008)
- Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. Zannettino, A.C., Holding, C.A., Diamond, P., Atkins, G.J., Kostakis, P., Farrugia, A., Gamble, J., To, L.B., Findlay, D.M., Haynes, D.R. J. Cell. Physiol. (2005)
- Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. Van Poznak, C., Cross, S.S., Saggese, M., Hudis, C., Panageas, K.S., Norton, L., Coleman, R.E., Holen, I. J. Clin. Pathol. (2006)
- Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Tsuda, E., Goto, M., Mochizuki, S., Yano, K., Kobayashi, F., Morinaga, T., Higashio, K. Biochem. Biophys. Res. Commun. (1997)
- Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Neville-Webbe, H.L., Cross, N.A., Eaton, C.L., Nyambo, R., Evans, C.A., Coleman, R.E., Holen, I. Breast Cancer Res. Treat. (2004)
- Role of osteoprotegerin (OPG) in cancer. Holen, I., Shipman, C.M. Clin. Sci. (2006)
- Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. Vitovski, S., Phillips, J.S., Sayers, J., Croucher, P.I. J. Biol. Chem. (2007)
- Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. Fu, M., Zhang, J., Lin Yg, Y., Zhu, X., Willson, T.M., Chen, Y.E. Biochem. Biophys. Res. Commun. (2002)
- Interleukin-11 as an osteoprotegerin-inducing factor in culture medium of blastic cells from a patient with acute megakaryocytic leukemia complicated with osteosclerosis. Sato, T., Matsunaga, T., Kida, M., Morii, K., Machida, T., Kawano, Y., Nakamura, K., Kuribayashi, K., Takada, K., Iyama, S., Sato, Y., Takayama, T., Takahashi, M., Kato, J., Chokki, M., Niitsu, Y. Am. J. Hematol. (2004)
- Interleukins in the control of osteoclast differentiation. Martin, T.J., Romas, E., Gillespie, M.T. Crit. Rev. Eukaryot. Gene Expr. (1998)
- Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Stilgren, L.S., Rettmer, E., Eriksen, E.F., Hegedüs, L., Beck-Nielsen, H., Abrahamsen, B. Bone (2004)
- Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. Schoppet, M., Al-Fakhri, N., Franke, F.E., Katz, N., Barth, P.J., Maisch, B., Preissner, K.T., Hofbauer, L.C. J. Clin. Endocrinol. Metab. (2004)